Ultrasound device could help warn of impending heart attack

"Existing state of the art technologies are capable of determining if plaque is present in the arteries, but can't tell whether it's vulnerable. And that makes it difficult to assess a patient's risk," said Dr Paul Dayton, a professor in the joint biomedical engineering department at North Carolina State University and Chapel Hill. "Our goal was to develop something that could effectively identify which plaques are vulnerable." There are two ultrasound techniques that can help identify vulnerable plaques, but both depend on the use of contrast agents called microbubbles. The first technique is to identify vasa vasorum in arteries. These are clusters of small blood vessels that often infiltrate arterial plaque, and which are considered indicators that a plaque is vulnerable. When microbubbles are injected into an artery, they follow the flow of the blood. If vasa vasorum are present, the microbubbles will flow through these blood vessels as well, effectively highlighting them on ultrasound images. The second technique is called molecular imaging, and relies on the use of targeted microbubbles. These microbubbles attach themselves to specific molecules that are more likely to be found in vulnerable plaques, making the plaques stand out on ultrasound images. "The problem is that existing intravascular ultrasound technology does not do a very good job in detecting contrast agents," noted Dr Xiaoning Jiang, an NC State associate professor of mechanical and aerospace engineering. "So we've developed a dual frequency intravascular ultrasound transducer which transmits and receives acoustic signals. "Operating on two frequencies allows us to do everything the existing intravascular ultrasound devices can do, but also makes it much easier for us to detect the contrast agents – or microbubbles – used for molecular imaging and vasa vasorum detection." The prototype device has performed well in laboratory testing, but the researchers say they are continuing to optimise the technology. They hope to launch pre-clinical studies in the near future.